Form 4: Enanta Pharmaceuticals Chief Legal Officer Reports Stock Option Exercise and Share Transactions
SEC Form 4
Nathaniel S. Gardiner, Chief Legal Officer of Enanta Pharmaceuticals, exercised stock options and acquired shares, while also reporting indirect ownership through a grantor retained annuity trust.
Summary
- On February 26, 2024, Nathaniel S. Gardiner, the Chief Legal Officer of Enanta Pharmaceuticals, exercised stock options to acquire 5,187 shares of common stock at a price of $8.99 per share.
- Following the transaction, Gardiner directly owns 75,688 shares of Enanta Pharmaceuticals common stock.
- Gardiner also indirectly owns 35,926 shares through a grantor retained annuity trust.
- He also holds options for 77,813 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. No explicit positive or negative implications can be derived.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 11/22/2023 | Date of grant for stock options, exercisable quarterly over four years. |
| 02/26/2024 | Date of stock option exercise and share acquisition. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.